1146 related articles for article (PubMed ID: 9815632)
21. Adjuvant treatment of high-risk breast cancer using multicycle high-dose chemotherapy and filgrastim-mobilized peripheral blood progenitor cells.
Basser RL; To LB; Begley CG; Juttner CA; Maher DW; Szer J; Cebon J; Collins JP; Russell I; Olver I
Clin Cancer Res; 1995 Jul; 1(7):715-21. PubMed ID: 9816037
[TBL] [Abstract][Full Text] [Related]
22. An EORTC pilot study of filgrastim (recombinant human granulocyte colony stimulating factor) as support to a high dose-intensive epiadriamycin-cyclophosphamide regimen in chemotherapy-naive patients with locally advanced or metastatic breast cancer.
Piccart MJ; Bruning P; Wildiers J; Awada A; Schornagel JH; Thomas J; Tomiak E; Bartholomeus S; Witteveen PO; Paridaens R
Ann Oncol; 1995 Sep; 6(7):673-7. PubMed ID: 8664188
[TBL] [Abstract][Full Text] [Related]
23. Multicycle high-dose chemotherapy and filgrastim-mobilized peripheral-blood progenitor cells in women with high-risk stage II or III breast cancer: five-year follow-up.
Basser RL; To LB; Collins JP; Begley CG; Keefe D; Cebon J; Bashford J; Durrant S; Szer J; Kotasek D; Juttner CA; Russell I; Maher DW; Olver I; Sheridan WP; Fox RM; Green MD
J Clin Oncol; 1999 Jan; 17(1):82-92. PubMed ID: 10458221
[TBL] [Abstract][Full Text] [Related]
24. A short course of induction chemotherapy followed by two cycles of high-dose chemotherapy with stem cell rescue for chemotherapy naive metastatic breast cancer.
Elias AD; Richardson P; Avigan D; Ibrahim J; Joyce R; Demetri G; Levine J; Warren D; Arthur T; Reich E; Wheele C; Frei E; Ayash L
Bone Marrow Transplant; 2001 Feb; 27(3):269-78. PubMed ID: 11277174
[TBL] [Abstract][Full Text] [Related]
25. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
26. Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxel.
Liu MC; Demetri GD; Berry DA; Norton L; Broadwater G; Robert NJ; Duggan D; Hayes DF; Henderson IC; Lyss A; Hopkins J; Kaufman PA; Marcom PK; Younger J; Lin N; Tkaczuk K; Winer EP; Hudis CA;
Cancer Treat Rev; 2008 May; 34(3):223-30. PubMed ID: 18234424
[TBL] [Abstract][Full Text] [Related]
27. Phase II trial of high-dose liposome-encapsulated doxorubicin with granulocyte colony-stimulating factor in metastatic breast cancer. TLC D-99 Study Group.
Shapiro CL; Ervin T; Welles L; Azarnia N; Keating J; Hayes DF
J Clin Oncol; 1999 May; 17(5):1435-41. PubMed ID: 10334528
[TBL] [Abstract][Full Text] [Related]
28. Dose-finding study of paclitaxel and cyclophosphamide in patients with advanced breast cancer.
Sessa C; Pagani O; Parma G; Goldhirsch A; Cavalli F
Semin Oncol; 1995 Jun; 22(3 Suppl 6):112-7. PubMed ID: 7541152
[TBL] [Abstract][Full Text] [Related]
29. Repetitive high-dose therapy with cyclophosphamide, thiotepa and docetaxel with peripheral blood progenitor cell and filgrastim support for metastatic and locally advanced breast cancer: results of a phase I study.
Prince HM; Rischin D; Toner GC; Seymour JF; Blakey D; Gates P; Eerhard S; Chapple P; Quinn M; Brettell M; Juneja S; Wolf M; Januszewicz EH; Richardson G; Scarlett J; Briggs P
Bone Marrow Transplant; 2000 Nov; 26(9):955-61. PubMed ID: 11100274
[TBL] [Abstract][Full Text] [Related]
30. Combination docetaxel/cyclophosphamide in patients with advanced solid tumors.
Valero V
Oncology (Williston Park); 1997 Aug; 11(8 Suppl 8):34-6. PubMed ID: 9364540
[TBL] [Abstract][Full Text] [Related]
31. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas.
Bokemeyer C; Franzke A; Hartmann JT; Schöber C; Arseniev L; Metzner B; Link H; Kanz L; Schmoll HJ
Cancer; 1997 Oct; 80(7):1221-7. PubMed ID: 9317171
[TBL] [Abstract][Full Text] [Related]
32. A randomised phase II study of conventional versus accelerated infusional chemotherapy with granulocyte colony-stimulating factor support in advanced breast cancer.
De Boer RH; Eisen TG; Ellis PA; Johnston SR; Walsh G; Ashley S; Smith IE
Ann Oncol; 2002 Jun; 13(6):889-94. PubMed ID: 12123334
[TBL] [Abstract][Full Text] [Related]
33. Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patients.
Tolcher AW; Cowan KH; Noone MH; Denicoff AM; Kohler DR; Goldspiel BR; Barnes CS; McCabe M; Gossard MR; Zujewski J; O'Shaughnessy JA
J Clin Oncol; 1996 Jan; 14(1):95-102. PubMed ID: 8558227
[TBL] [Abstract][Full Text] [Related]
34. Multiple cycles of high dose chemotherapy supported by hematopoietic progenitor cells as treatment for patients with advanced malignancies.
Long GD; Negrin RS; Hoyle CF; Kusnierz-Glaz CR; Schriber JR; Blume KG; Chao NJ
Cancer; 1995 Sep; 76(5):860-8. PubMed ID: 8625190
[TBL] [Abstract][Full Text] [Related]
35. The impact of schedule on acute toxicity and dose-intensity of high-dose chemotherapy with epirubicin and cyclophosphamide plus colony stimulating factors in advanced breast cancer.
De Placido S; Lauria R; Carlomagno C; Perrone F; De Laurentiis M; Gallo C; Martignetti A; Bellelli T; Limite G; Petrella G; Bianco AR
Int J Oncol; 1999 Aug; 15(2):339-46. PubMed ID: 10402245
[TBL] [Abstract][Full Text] [Related]
36. Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies.
Chow WA; Synold TW; Tetef ML; Longmate J; Frankel P; Lawrence J; Al-Khadimi Z; Leong L; Lim D; Margolin K; Morgan RJ; Raschko J; Shibata S; Somlo G; Twardowski P; Yen Y; Doroshow JH
Cancer Chemother Pharmacol; 2004 Sep; 54(3):241-8. PubMed ID: 15173955
[TBL] [Abstract][Full Text] [Related]
37. Double dose-intensive chemotherapy with autologous marrow and peripheral-blood progenitor-cell support for metastatic breast cancer: a feasibility study.
Ayash LJ; Elias A; Wheeler C; Reich E; Schwartz G; Mazanet R; Tepler I; Warren D; Lynch C; Gonin R
J Clin Oncol; 1994 Jan; 12(1):37-44. PubMed ID: 7505807
[TBL] [Abstract][Full Text] [Related]
38. A Phase I dose escalation trial of continuous infusion paclitaxel to augment high dose cyclophosphamide and thiotepa plus stem cell rescue for the treatment of patients with advanced breast carcinoma.
Zimmerman TM; Grinblatt DL; Malloy R; Williams SF
Cancer; 1998 Oct; 83(8):1540-5. PubMed ID: 9781947
[TBL] [Abstract][Full Text] [Related]
39. Pilot trial of infusional cyclophosphamide, doxorubicin, and etoposide plus didanosine and filgrastim in patients with human immunodeficiency virus-associated non-Hodgkin's lymphoma.
Sparano JA; Wiernik PH; Hu X; Sarta C; Schwartz EL; Soeiro R; Henry DH; Mason B; Ratech H; Dutcher JP
J Clin Oncol; 1996 Nov; 14(11):3026-35. PubMed ID: 8918501
[TBL] [Abstract][Full Text] [Related]
40. Dose escalation of biweekly cyclophosphamide, doxorubicin, vincristine, and prednisolone using recombinant human granulocyte colony stimulating factor in non-Hodgkin's lymphoma.
Tanosaki R; Okamoto S; Akatsuka N; Ishida A; Michikawa N; Masuda Y; Uchida H; Murata M; Kizaki M; Ikeda Y
Cancer; 1994 Oct; 74(7):1939-44. PubMed ID: 7521788
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
